Arkana
Arkana is a biotech company developing oral, first-in-class small-molecule therapies for obesity and metabolic disease by leveraging insights from animals with extreme metabolic adaptations. Its lead programs target both appetite reduction and energy expenditure, with an early candidate showing better GI tolerability than GLP-1 therapies in proof-of-concept studies. The platform is grounded in peer-reviewed research published in Nature Metabolism.
- Biotechnology
- Drug Discovery & Therapeutics
- Healthcare Technology
Funding
Founders
Product
Problem
Obesity and metabolic disease affect over a billion people worldwide, yet current treatments like GLP-1 medicines face significant tolerability issues, high costs, and discontinuation rates that leave many patients without a durable solution. Existing therapies also rely heavily on a single mechanism, limiting options for patients who do not respond or cannot tolerate them.
Solution
Arkana's extreme biology platform studies how animals have evolved metabolic adaptations to survive conditions like prolonged fasting and extreme weight fluctuations, then translates those insights into new drug candidates. The company is developing two distinct oral small-molecule programs that address both sides of the energy-balance equation: ARK-100 targets the brain to reduce calorie intake with better GI tolerability than GLP-1 therapies, while ARK-200 aims to increase energy expenditure by raising basal calorie burn. Both are once-daily pills designed to offer differentiated, first-in-class alternatives in a market dominated by injectable incretins.
Target Audience
Primary customers are patients with obesity and metabolic disease who need effective, tolerable, non-injectable treatment options, as well as healthcare providers and payers seeking alternatives to current GLP-1 therapies.
Features
- ARK-100: orally available small molecule that reduces food intake via the brain, with proof-of-concept data showing meaningful weight loss and improved GI tolerability versus GLP-1 therapies
- ARK-200: mechanistically distinct program designed to raise resting energy expenditure, complementing appetite-suppression approaches
- Both programs are once-daily oral small molecules, offering a non-injectable alternative to current standard-of-care treatments
- Platform is based on studying naturally evolved metabolic adaptations in animals, providing a novel drug discovery approach validated by peer-reviewed publication in Nature Metabolism